J&J Bails on Capricor Stem Cell Partnership

Jul 10, 2017

After three and a half years, Johnson & Johnson is walking away from a partnership with Capricor Therapeutics focused on the use of stem cells to treat cardiovascular disease.

J&J's Janssen unit has decided not to exercise its option to exclusively license the California-based biotech's lead candidate CAP-1002 (allogeneic cardiosphere-derived cells) for development and commercialization in the field of cardiology. Capricor will retain all rights to develop and commercialize CAP-1002 for any indication, either independently or in collaboration with third parties.

The news does not come as a surprise after CAP-1002 missed the target in a phase 1/2 study involving patients who had suffered a heart attack. Additionally, in April, interim results from a trial in Duchenne muscular dystrophy revealed promising results for the new indication, which lies outside the scope of Capricor's license with J&J.

Read the press release



Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments